

20 January 2021

DeepMatter Group plc
("DeepMatter", the "Company" or "the Group")

DeepMatter subsidiary signs data licensing agreement with the Life Science business of Merck

DeepMatter Group plc, the AIM-quoted company focusing on digitising chemistry, is pleased to announce that one of its wholly owned subsidiaries has entered into a multi-year, limited-use data licensing agreement with the Life Science business of Merck to provide proprietary chemical structure and reaction data content to Merck's selected application.

Merck, a leading science and technology company, operates across Healthcare, Life Science and Performance Materials. The terms of the data license agreement have not been disclosed.

Mark Warne, CEO of DeepMatter commented: *"We are delighted to have entered into this license with Merck, a company dedicated to making research and biotech simpler, faster and safer."*

For more information, please contact:

DeepMatter Group plc
Mark Warne, Chief Executive Officer

T: 0141 548 8156

**Canaccord Genuity Limited (Nominated
Advisor and Broker)**

Bobbie Hilliam / Angelos Vlatakis

T: 020 7523 8000

Alma PR

Caroline Forde / Harriet Jackson / Kieran Breheny

T: 020 3405 0205

deepmatter@almapr.co.uk

About DeepMatter Group plc

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. It has developed and is commercialising data rich platform technologies, including software and laboratory hardware, focused on applications to improve R&D productivity and discovery using Machine Learning / Artificial Intelligence.

DeepMatter's technologies allow chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. They are designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

About Merck

Merck, a leading science and technology company, operates across Healthcare, Life Science and Performance Materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.

www.merckgroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTKKLFFFFLBBBE